In view of the favourable market conditions and on the back of the strong M&A activity year-to-date,
\nEurofins has decided that this is the right time to access the debt capital markets in order to refinance its
\n2018 bond as well as enhance its liquidity position.<\/p>\n
Eurofins continues to invest in attractive markets where the Group sees growth opportunities with the
\nobjective to create long-term value for its shareholders. While Eurofins\u2019 business activity is in-line with
\nboth its 2020 mid-term plan and 2017 objectives, as announced on last February 28th, its M&A activity in
\nparticular, has been ahead of plan since the beginning of the year.<\/p>\n
As of today, including the Amatsi transaction announced on July 10th, Eurofins has signed and\/or closed
\ndeals representing an aggregate amount of expected annual pro forma revenues close to EUR 270m in
\n2017 thereby exceeding its annual M&A revenue target (EUR 200m) in only six months. The larger
\ntransactions included in this total have been described in press releases issued since the start of the
\nyear. Overall the EBITDA margin of the companies acquired is already in the high double digit area,
\nclose to the Group\u2019s 20% objective. The corresponding consideration is of the order of EUR 475m with
\nup to less than 10% additional contingent earn-out subject to significant profit growth. Eurofins also
\nanticipates that the remainder of the year should continue to remain strong in terms of M&A activity.<\/p>\n
In terms of liquidity, Eurofins closed the year ending 31 December 2016 with EUR 826m of available
\ncash, which has financed the intense M&A activity in the first six months of this year (c. EUR 300m,
\nexcluding the Amatsi transaction which should be closed later during the year), Bond and Hybrid capital
\ncoupons in excess of EUR 60m paid in H1 2017 and the 2017 dividends of EUR 34m paid early July; it
\nwill also be used to pay for the buy-out of Bio-Access minority shareholders for approximately EUR
\n100m scheduled in early August; all the above representing a total of c. EUR 500m of cash
\ndisbursements. Of course Eurofins also continues to generate operating cash flow in line with its
\nobjectives.<\/p>\n
Given the current attractive credit market conditions and potential future rate increases, it seems an
\nopportune time to contemplate a new EUR 500m seven year bond offering, that will strengthen our
\nliquidity position for corporate activity in the remainder of 2017 as well as extend our debt maturity
\nprofile. It will also help us refinance our EUR 300m bond that matures in November 2018.<\/p>\n
Comment from Dr. Gilles Martin, Eurofins CEO: \u201cI am happy to report on strong M&A results for the BofA Merrill Lynch and BNP Paribas will act as global coordinators and Cr\u00e9dit Agricole CIB, Natixis and The bonds will be listed on the regulated market of the Luxembourg stock exchange. The bonds are not Eurofins Scientific SE (EUFI.PA, unrated), a global leader in bioanalytical testing, announces the
\nfirst half of the year where we added several profitable, high growth and defensive companies to our
\nportfolio. We continue to examine several interesting opportunities, while sticking to our financial
\ndiscipline of maintaining a sound capital structure, and creating long-term value for our shareholders
\nand investors. This discipline is exemplified by the fact that Eurofins has continued to focus on smaller
\ntransactions at a reasonable overall multiple.”<\/em><\/p>\n
\nUniCredit Bank will act as joint bookrunners for the transaction.<\/p>\n
\nregistered under the US Securities Act of 1933 as amended (the \u201cSecurities Act\u201d), and may not be
\noffered or sold in the United States (as such term is defined in Regulation S under the Securities Act)
\nunless registered under the Securities Act or pursuant to an exemption from such registration. <\/p>\n","protected":false},"excerpt":{"rendered":"
\npotential launch of an offering for a EUR 500m seven year senior unsecured bond, maturing in 2024,
\nsubject to market conditions.<\/p>\n","protected":false},"author":20,"featured_media":64578,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1470],"tags":[1856,1859,1671,1681,1437,2103],"_links":{"self":[{"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/posts\/64580"}],"collection":[{"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/comments?post=64580"}],"version-history":[{"count":0,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/posts\/64580\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/media\/64578"}],"wp:attachment":[{"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/media?parent=64580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/categories?post=64580"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/tags?post=64580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}